AzTrials
AzTrials

Spinal Cord InjuryDBS-SCINCT03053791

Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait

A study testing Deep brain stimulation in mesencephalic locomotor region and Implantation of a Deep brain stimulation system in people with Spinal Cord Injury, run by University of Zurich at 1 site in Switzerland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Spinal cord injuries are anatomically mostly incomplete, showing tissue bridges of the spinal cord at the injury site. Of the 60% functionally incomplete patients, about half face a life in the wheelchair. Besides conventional rehabilitation, no prominsing further treatment options exist. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Spinal Cord Injury
What is being tested?
Deep brain stimulation in mesencephalic locomotor region and Implantation of a Deep brain stimulation system
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5 participants
Where
1 siteSwitzerland
Study dates
15 Mar 2018to Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Informed Consent
  • Participation in two assessment sessions before enrollment (Screening and baseline)
  • Willingness and ability to comply with the protocol and to attend required study training and visits
  • Male or female subjects
  • Age 18-75
  • Motor incomplete SCI
Show all 13Show fewer
  • Level of lesion: T10 and above, based on AIS level, preservation of sacral function
  • Focal spinal cord disorder caused by either trauma or non-traumatic and non-progressive condition (like hemorrhage, benign tumor)
  • Minimum 3 months of recovery after SCI
  • Completed in-patient rehabilitation program
  • WISCI II, level >2 (0-20 items): assistance of one or more persons. Ability to walk at least 10 meters
  • Stable medical and physical condition.
  • Adequate care-giver support and access to appropriate medical care in patient's home community

Who cannot join

  • Enrollment of the investigator, his/her family members, employees and other dependent persons
  • Limitation of standing and walking function based on accompanying (CNS) disorders
  • Cardiovascular disorders restricting physical training or peripheral nerve disorders
  • Implanted technical devices (pacemaker, defibrillator)
  • History of significant autonomic dysreflexia
  • Cognitive disorders/brain damage
Show all 16Show fewer
  • Drug refractory epilepsy
  • Severe joint contractures disabling or restricting lower limb movements
  • Haematological disorders with increased risk of bleeding during surgical interventions
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Congenital or acquired lower limb abnormalities (affection of joints and bone)
  • Women who are pregnant or breast feeding or planning a pregnancy during the course of the study
  • Lack of safe contraception
  • Inability of the participant to follow the procedures of the study, e.g. due to language problems, psychological problems, dementia etc.
  • Known or suspected non-compliance, drug or alcohol abuse
  • Current or prior malignancy

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Switzerland1 site, 1 recruiting
  • Balgrist University Hospital

    Zurich, 8008

    Iris Krüsi, +4144386 ext. 1111, DBS-SCI@balgrist.ch

    Armin Curt, MD

    Recruiting

Other trials in Switzerland

About this study

Official title: A Phase I/II Open-label Multicenter Trial to Evaluate Safety and Preliminary Efficacy of Unilateral Deep Brain Stimulation of the Mesencephalic Locomotor Region in Patients With Incomplete Spinal Cord Injury

Spinal cord injuries are anatomically mostly incomplete, showing tissue bridges of the spinal cord at the injury site. Of the 60% functionally incomplete patients, about half face a life in the wheelchair. Besides conventional rehabilitation, no prominsing further treatment options exist. One of the most plastic systems involved in locomotion is the pontomedullary reticulospinal tract, which is the oldest locomotor command system existing in most vertebrates, including primates. Muscle activation patterns for limb movements are programmed in the spinal cord and have to be activated and coordinated through commands from the so called mesencephalic locomotor region (MLR). The MLR consists of nerve cells in the lower mesencephalic tegmentum sending uni- and bilateral signals through the medullary reticulospinal tracts. Classical physiological studies showed that electrical stimulation of the MLR induce locomotion. For the first time this approach was transferred and recently published in a model of induced incomplete spinal cord injury by the Schwab group. Rats severly impaired in motor hindlimb control with only 10-20% spared white matter, recovered with fully functional weight bearing locomotion under MLR deep brain stimulation (DBS). Even rats with only 2-10% spared white matter regained weight supporting stepping. DBS is a clinical standard treatment option in patients with movement disorders but does not relieve all symptoms. Therefore, small studies of MLR stimulations have been safely used in Parkinsonian patients showing freezing of gait and frequent falls with variable results. In a translational approach, we aim at performing a multidisciplinary phase one clinical trial with 5 patients and incomplete spinal cord injury. With the means of our established universitary setup for DBS treatments the operations will be performed unilaterally under local anaesthesia in the Division of Neurosurgery, USZ, with perioperative electrophysiological recordings, clinical assessments and gait analysis under test stimulation in the Spinal Cord Injury Center Balgrist.

Read the detailed description

After approval by the local ethics committee we will perform a phase I open-label trial to evaluate safety and preliminary efficacy of unilateral deep brain stimulation of the mesencephalic locomotor region in patients with incomplete spinal cord injury. Male or female subjects (18-75 year-old) with completed in-patient rehabilitation will be enrolled for screening evaluations at minimum 3 months post-injury. DBS operation will be performed at minimum 3 months post-injury. Primary endpoint will be improvement of locomotion as determined by the 6-Minute walking test.

Secondary endpoints will be electrophysiological/clinical and image based characterization of the mesencephalic locomotor region, questionnaire based/ professional assessments of quality of life, pain, micturition, sleep behavior, cognitive function and psychiatric evaluations (mood, anxiety, impulse control, delusional and affective disorders). The study population will consist of 5 subjects and the study period for each patient is 6 months postoperatively. Briefly, candidate subjects, able to stand with a walker or 2 crutches and with stable neurological condition will have to meet all of the inclusion and none of the exclusion criteria. Subjects will have preoperative examinations (e.g. MRI scans of the head and spine, neuropsychological, psychiatric and sleep status etc.) according to our standard protocols of DBS for movement disorders, especially Parkinson's disease, based on certification criteria of Highly-Specialized-Medicine DBS centers in Switzerland. Neurological assessments for spinal cord injury impairment as defined by study protocol will be performed at the University Hospital Balgrist.

The operation will be performed in the Division of Neurosurgeon by the neurosurgical PI of this study: awake subjects will have their heads fixed in a stereotactic ring with local anesthesia and high resolution head scans will be performed to define the stereotactic space for targeting through anatomical landmarks defined on individual MRI as described in the literature. In contrast to bilateral implantations in Parkinsonian patients, here, a single burr hole will be opened under local anesthesia on the contralateral side of the worse lower extremity of the subject. Microelectrode recordings of single-cells as well as local field potentials will be mapped starting 1 cm prior the MLR target. Four states will be analyzed: resting state, imagination of walking, passive and active lower limb movement. These recordings will help to further determine the places of stimulation as the next step of surgery. Here, slow increases of the stimulation amplitude with a constant frequency of e.g. 50Hz will be applied to determine activation of lower limb muscle activity with electroneuromyographic recordings and detection of possible amelioration of intended active movements. Since the subject is awake, possible side effects will be professionally monitored at each site of stimulation and amplitude. Next, the electrode for recording and stimulation will be exchanged with the standard 8-contact directional DBS electrode for Parkinson's disease patients (1.28 mm in diameter, 1.5mm length of each contact and 0.5 mm spacing in between). All subjects will receive an intraoperative head scan to verify correct placement and accuracy. If refinement is not necessary, the first operative procedure will be regarded as finished and the subject will be transferred to the intermediate care unit overnight to recover from surgery. The surgeon will decide, if the impulse generator will be implanted in the same surgery or delayed. Subjects will undergo regular assessments until discharge and further on in an outpatient setup around day 30 post-surgery, as well as 3 and 6 months afterwards. Rehabilitative postoperative treatment will be assisted by using the recently CE certificated and award winning FLOAT system ("Free Levitation for Overground Active Training") which allows robotic multidirectional relief of body weight and exact gait/posture analysis.

Being tested
Deep brain stimulation in mesencephalic locomotor region, Implantation of a Deep brain stimulation system
Keywords
Deep brain stimulation, DBS, Spinal cord injury, SCI, Paraplegia, Mesencephalic locomotor region, MLR, Pedunculopontine nucleus, PPN
Medical subject headings
Spinal Cord Injuries, Paraplegia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Deep brain stimulation in mesencephalic locomotor regionProcedure or surgery

    Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait

  • Implantation of a Deep brain stimulation systemDevice

    Implantation of a Medtronic Percept PC Impulse Generator for chronic Stimulation of the selected target.

Study groups in NCT03053791
Study groupRoleWhat they receive
Intervention groupExperimentalSingle-armed study. All patients will receive treatment.
Receives: Procedure: Deep brain stimulation in mesencephalic locomotor region; Device: Implantation of a Deep brain stimulation system

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in 6 Minute Walk Test at baseline and 6 months post intervention

    Standardized test. Patient is asked to walk for 6 minutes. Result is the distance covered

    Measured: preoperative, 6 months post intervention

Secondary outcomes (18)
  1. Change in 10 Meter Walking Test towards baseline

    Standardized test. Patient is asked to walk 10 meters as quickly as possible. Result is the speed (m/s)

    Measured: preoperative, early postop, before discharge, 1,3,6 months follow-up

  2. Change in Timed Up and Go test (TUG) towards baseline

    Standardized test. Patient is asked to stand up from a sitting into Standing Position and walk 3 m and return to seated position. Result ist time.

    Measured: preoperative, early postop, before discharge, 1,3,6 months follow-up

  3. Kinematic assessment during overground and treadmill walking

    Individuals are secured using the FLOAT.

    Measured: preoperative, early postop, before discharge, 1,3,6 months follow-up

  4. Change in Spinal cord Independence measure (SCIM III) towards baseline

    Standardized tool measuring the degree of independence of the subject. Result is score.

    Measured: preoperative, early postop, before discharge, 1,3,6 months follow-up

  5. Change in Walking index for spinal cord injury (WISCI II) towards baseline

    Standardized tool measuring the subject's ability to walk. Result is score.

    Measured: preoperative, early postop, before discharge, 1,3,6 months follow-up

  6. Long-term monitoring of physical activity

    Wearable and wireless sensors are mounted to the patient and wheelchair for constant monitoring of physical activity

    Measured: Continuously between discharge and 6 months follow-up

  7. Electrophysiology

    SSEPs, MEPs, DBS-EPs, LFPs, EMG

    Measured: Baseline and several time-points throughout the study.

  8. Changes in Electroencephalography towards baseline

    Evaluation for the occuracne of EEG abnormalities

    Measured: preoperative, intraoperative, early postop, 6 months follow-up

  9. Change in Quality of life towards baseline

    Standardized QOL tool (SF-36). Result is score.

    Measured: preoperative, 1,3,6 months follow-up

  10. Change in lower urinary tract function towards baseline

    Standardized tools QUALIVEEN, bladder diary, urodynamic assessments, renal and bladder ultrasound.

    Measured: preoperative, 6 months follow-up

  11. Change in sexual functions towards baseline

    Use of the standardized tools FSFI (Female Sexual Function Index), result is score respectively IIEF (International Index of Erectile Function), result is score

    Measured: preoperative, 1,3,6 months follow-up

  12. Change in spasticity towards baseline

    Use of the standardized tool MAS (Modified Ashword Scale). Result is score.

    Measured: preoperative, early postop, before discharge, 1,3,6 months follow-up

  13. Changes in ASIA impairment scale (AIS)

    Assment of neurological status of individual with SCI

    Measured: preoperative, early postop, before discharge, 1,3,6 months follow-up

  14. Change in Upper limb Sensation, Strength and Prehension towards baseline

    Standardized tool GRASSP

    Measured: preoperative, 6 months follow-up

  15. Change in sleepiness towards baseline

    Standardized tool Epworth Sleepiness Scale

    Measured: preoperative, 1,3,6 months follow-up

  16. Change in Fatigue towards baseline

    Standardized tool Fatigue Severity Scale

    Measured: preoperative, 1,3,6 months follow-up

  17. Change in pain sensation towards baseline

    Standardized tools EPAF and SCIPI

    Measured: preoperative, 1,3,6 months follow-up

  18. Change in 6 Minute Walk Test at other timepoints towards baseline

    Standardized test. Patient is asked to walk for 6 minutes. Result is the distance

    Measured: Screening, early postop, before discharge, 1,3 months follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Feb 2017
  2. Study start15 Mar 2018
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Single group of patients with spinal cord injury and spared fibers.
Masking
None (open label)
Enrolment
5 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03053791
Sponsor's protocol ID
SNCTP000000598
Acronym
DBS-SCI
Status last verified
May 2026
First submitted
26 Apr 2016
Last updated
29 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Hofer AS, Scheuber MI, Sartori AM, Skorup I, Gascho D, Colacicco G, Kiseleva A, Curt A, Stieglitz LH, Schwab ME. Stereotactic rodent-to-human approximation of the mesencephalic cuneiform nucleus to guide deep brain stimulation. Brain Stimul. 2026 Mar-Apr;19(2):103066. doi: 10.1016/j.brs.2026.103066. Epub 2026 Mar 3.

    PubMed 41786287
  • Hofer AS, Stieglitz LH, Bolliger M, Filli L, Cathomen A, Willi R, Lerch I, Krusi I, Giagiozis M, Meyer C, Schubert M, Hubli M, Kessler TM, Demko L, Baumann CR, Imbach L, Oertel MF, Prusse A, Kiseleva A, Regli L, Schwab ME, Curt A. Cuneiform Nucleus Stimulation Can Assist Gait Training to Promote Locomotor Recovery in Individuals With Incomplete Tetraplegia. Ann Neurol. 2026 Jan;99(1):161-177. doi: 10.1002/ana.78026. Epub 2025 Sep 10.

    PubMed 40927915
  • Stieglitz LH, Hofer AS, Bolliger M, Oertel MF, Filli L, Willi R, Cathomen A, Meyer C, Schubert M, Hubli M, Kessler TM, Baumann CR, Imbach L, Krusi I, Prusse A, Schwab ME, Regli L, Curt A. Deep brain stimulation for locomotion in incomplete human spinal cord injury (DBS-SCI): protocol of a prospective one-armed multi-centre study. BMJ Open. 2021 Sep 30;11(9):e047670. doi: 10.1136/bmjopen-2020-047670.

    PubMed 34593490

Questions about this trial

What is this clinical trial studying?

A study testing Deep brain stimulation in mesencephalic locomotor region and Implantation of a Deep brain stimulation system in people with Spinal Cord Injury, run by University of Zurich at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 29 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lennart H Stieglitz, MD (+4144255 ext. 9905, Lennart.Stieglitz@usz.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in 6 Minute Walk Test at baseline and 6 months post intervention (time frame: preoperative, 6 months post intervention). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03053791, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in